Alimera licenses Emory's triphenylmethanes for eye disease

Alimera Sciences has entered into a second exclusive worldwide agreement with fellow USA-based Emory University to explore oxidative stress management, specifically the reduction of reactive oxygen species, as a treatment for ophthalmic diseases.

The agreement gives Alimera the exclusive option to license a class of small-molecule compounds known as triphenylmethanes as a potential treatment for ocular disorders such as diabetic retinopathy and the dry form of age-related macular degeneration, particularly the late stage of this condition, which is known as geographic atrophy. This agreement is in addition to the September 2007 option to license the nicotinamide adenine dinucleotide phosphate-reduced form oxidase inhibitors for similar treatments.

If the option is exercised, Alimera will hold an exclusive worldwide license for these agents for ophthalmic indications. Also included in the agreement is an exclusive right to sub-license in ophthalmology and the exclusive option for non-ophthalmic use. The US drugmaker will be responsible for both the development and commercialization of the compounds, while Emory will receive milestone payments and royalties on net sales. Further financial details were not disclosed.